Preexisting maternal immunity to AAV but not Cas9 impairs in utero gene editing in mice
Journal of Clinical Investigation · 2024
DOI: 10.1172/jci179848 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von John S Riley und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for Fetal Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Dependovirus, Gene Editing. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
In utero gene editing (IUGE) is a potential treatment for inherited diseases that cause pathology before or soon after birth. Preexisting immunity to adeno-associated virus (AAV) vectors and Cas9 endonuclease may limit postnatal gene editing. The tolerogenic fetal immune system minimizes a fetal immune barrier to IUGE. However, the ability of maternal immunity to limit fetal gene editing remains a question. We investigated whether preexisting maternal immunity to AAV or Cas9 impairs IUGE. Using a combination of fluorescent reporter mice and a murine model of a metabolic liver disease, we demonstrated that maternal anti-AAV IgG antibodies were efficiently transferred from dam to fetus and impaired IUGE in a maternal titer–dependent fashion. By contrast, maternal cellular immunity was inefficiently transferred to the fetus, and neither maternal cellular nor humoral immunity to Cas9 impaired IUGE. Using human umbilical cord and maternal blood samples collected from mid- to late-gestation pregnancies, we demonstrated that maternal-fetal transmission of anti-AAV IgG was inefficient in midgestation compared with term, suggesting that the maternal immune barrier to clinical IUGE would be less relevant at midgestation. These findings support immunologic advantages for IUGE and inform maternal preprocedural testing protocols and exclusion criteria for future clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Fetal Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island, USA.
- Division of Cardiology, Department of Medicine, and.
- Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Center for Fetal Diagnosis and Treatment and.
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
- NINDS NIH HHS
- NICHD NIH HHS
- NIH Office of the Director
- NIH, NIDDK
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- American College of Surgeons
Zitieren
APA
Riley, J. S., Luks, V. L., Berkowitz, C. L., Dumitru, A. M., Kus, N. J., Dave, A., Menon, P., De Paepe, M. E., Jain, R., Li, L., Dugoff, L., Teefey, C. P., Alameh, M. G., Zoltick, P. W., & Peranteau, W. H. (2024). Preexisting maternal immunity to AAV but not Cas9 impairs in utero gene editing in mice. Journal of Clinical Investigation. https://doi.org/10.1172/jci179848
Vancouver
Riley JS, Luks VL, Berkowitz CL, Dumitru AM, Kus NJ, Dave A, et al. Preexisting maternal immunity to AAV but not Cas9 impairs in utero gene editing in mice. Journal of Clinical Investigation. 2024. doi:10.1172/jci179848
BibTeX
@article{Riley2024,
author = {Riley, John S and Luks, Valerie L and Berkowitz, Cara L and Dumitru, Ana Maria and Kus, Nicole J and Dave, Apeksha and Menon, Pallavi and De Paepe, Monique E and Jain, Rajan and Li, Li and Dugoff, Lorraine and Teefey, Christina Paidas and Alameh, Mohamad-Gabriel and Zoltick, Philip W and Peranteau, William H},
title = {Preexisting maternal immunity to AAV but not Cas9 impairs in utero gene editing in mice},
journal = {Journal of Clinical Investigation},
year = {2024},
doi = {10.1172/jci179848}
}
EUVIMED